Strs Ohio Has $143.75 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Strs Ohio trimmed its Thermo Fisher stake by 1.4% to 248,077 shares valued at $143.75 million, representing about 0.07% of the company and its 26th-largest holding.
• Earnings beat: Thermo Fisher reported Q EPS of $5.44 (vs. $5.25 expected) and $11.01 billion revenue, set FY2026 EPS guidance of 24.64–25.12, and carries a MarketBeat consensus rating of Buy with a $623.05 target.
• Insiders sold a total of 5,800 shares over the last quarter (including CEO and COO sales), and the company increased its quarterly dividend to $0.47 ($1.88 annualized, ~0.4% yield).

Strs Ohio lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 248,077 shares of the medical research company's stock after selling 3,447 shares during the period. Thermo Fisher Scientific accounts for 0.5% of Strs Ohio's holdings, making the stock its 26th biggest holding. Strs Ohio owned about 0.07% of Thermo Fisher Scientific worth $143,748,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Thermo Fisher Scientific by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock worth $19,778,774,000 after purchasing an additional 288,296 shares during the period. Capital World Investors lifted its holdings in shares of Thermo Fisher Scientific by 7.4% during the third quarter. Capital World Investors now owns 10,285,145 shares of the medical research company's stock worth $4,988,132,000 after purchasing an additional 706,572 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Thermo Fisher Scientific by 21.0% during the third quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company's stock worth $2,874,069,000 after purchasing an additional 1,028,125 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Thermo Fisher Scientific by 54.7% during the third quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company's stock worth $1,732,422,000 after purchasing an additional 1,262,967 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Thermo Fisher Scientific by 5.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,087,666 shares of the medical research company's stock worth $1,789,148,000 after purchasing an additional 150,668 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Analysts Set New Price Targets

TMO has been the topic of several recent analyst reports. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a report on Friday, April 24th. TD Cowen dropped their price objective on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating on the stock in a report on Friday, January 30th. Barclays decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating for the company in a research report on Tuesday, April 14th. UBS Group reissued a "neutral" rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Finally, Evercore reissued an "outperform" rating and set a $650.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Buy" and a consensus target price of $623.05.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 5,800 shares of company stock worth $2,963,544 over the last quarter. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $469.39 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The company has a market cap of $174.43 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 2.12 and a beta of 0.88. The business's 50 day simple moving average is $496.11 and its 200 day simple moving average is $547.71.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion for the quarter, compared to analysts' expectations of $10.86 billion. During the same period in the prior year, the company posted $5.15 EPS. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were paid a $0.47 dividend. The ex-dividend date was Friday, March 13th. This represents a $1.88 annualized dividend and a yield of 0.4%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's dividend payout ratio is currently 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.